Uniqure N.V. (QURE) — 8-K Filings

8-K Filings (23)

• 8-K Filing — May 5, 2026
• 8-K Filing — Apr 30, 2026
• 8-K Filing — Dec 4, 2025
• uniQure N.V. Files 8-K Report — Nov 3, 2025 Risk: low
  On November 3, 2025, uniQure N.V. filed an 8-K report. The filing primarily concerns financial statements and exhibits, along with other events and a Regulation
• uniQure N.V. Files 8-K for Material Definitive Agreement — Sep 29, 2025 Risk: medium
  On September 25, 2025, uniQure N.V. entered into a material definitive agreement. The filing also indicates other events and includes financial statements and e
• uniQure N.V. Files 8-K Report — Sep 24, 2025 Risk: low
  On September 24, 2025, uniQure N.V. filed an 8-K report. The filing primarily consists of financial statements and exhibits, with no specific material events or
• uniQure N.V. Enters Material Definitive Agreement — Jul 29, 2025 Risk: medium
  On July 29, 2025, uniQure N.V. entered into a material definitive agreement. The filing also includes financial statements and exhibits related to this agreemen
• uniQure N.V. Files 8-K: Director Changes, Officer Appointments, and Shareholder Votes — Jun 13, 2025 Risk: low
  On June 11, 2025, uniQure N.V. filed an 8-K report detailing several key events. The company announced the election of new directors, the appointment of certain
• uniQure N.V. Files 8-K Report — Jun 2, 2025 Risk: low
  On June 2, 2025, uniQure N.V. filed an 8-K report. The filing primarily concerns financial statements and exhibits, with no specific material events or disclosu
• uniQure Appoints New Chief Medical Officer — Apr 16, 2025 Risk: low
  On April 15, 2025, uniQure N.V. announced the appointment of Dr. Olav Hellebostad as Chief Medical Officer, effective April 16, 2025. Dr. Hellebostad will overs
• uniQure N.V. Files 8-K: Material Definitive Agreement — Jan 8, 2025 Risk: medium
  On January 7, 2025, uniQure N.V. entered into a material definitive agreement. The company also reported other events and filed financial statements and exhibit
• uniQure N.V. Files 8-K Report — Dec 10, 2024 Risk: low
  On December 10, 2024, uniQure N.V. filed an 8-K report to disclose financial statements and exhibits. The filing does not contain specific financial figures or
• uniQure N.V. Files 8-K Report — Nov 21, 2024 Risk: low
  On November 21, 2024, uniQure N.V. filed an 8-K report. The filing primarily concerns financial statements and exhibits, with no specific material events or dis
• uniQure N.V. Files 8-K Report — Oct 15, 2024 Risk: low
  On October 15, 2024, uniQure N.V. filed an 8-K report. The filing primarily concerns Regulation FD disclosures and financial statements/exhibits. No specific fi
• uniQure N.V. Files 8-K Report — Sep 23, 2024 Risk: low
  On September 23, 2024, uniQure N.V. filed an 8-K report. The filing primarily concerns Regulation FD disclosures and financial statements/exhibits, with no spec
• uniQure N.V. Files 8-K Report — Aug 15, 2024 Risk: low
  On August 15, 2024, uniQure N.V. filed an 8-K report. The filing primarily concerns Regulation FD Disclosure and Financial Statements and Exhibits. No specific
• uniQure Announces CMO Departure, Appoints Interim — Jul 23, 2024 Risk: medium
  On July 22, 2024, uniQure N.V. announced the departure of its Chief Medical Officer, Dr. Robert Kotin, effective July 26, 2024. The company also announced the a
• uniQure N.V. Files 8-K Report — Jul 9, 2024 Risk: low
  On July 9, 2024, uniQure N.V. filed an 8-K report. The filing primarily concerns financial statements and exhibits, along with other events and a Regulation FD
• uniQure N.V. Enters Material Definitive Agreement — Jul 1, 2024 Risk: medium
  On June 29, 2024, uniQure N.V. entered into a material definitive agreement. The filing does not disclose specific details of the agreement or any associated do
• uniQure Appoints New CEO, Elects Directors — Jun 20, 2024 Risk: medium
  On June 18, 2024, uniQure N.V. announced the appointment of Dr. Olav Hellebø as Chief Executive Officer, effective July 1, 2024. Dr. Hellebø, who has been a mem
• uniQure N.V. Files 8-K Report — Jun 3, 2024 Risk: low
  On June 3, 2024, uniQure N.V. filed an 8-K report. The filing primarily concerns Regulation FD Disclosure and Financial Statements and Exhibits. No specific fin
• uniQure Announces Executive Changes and AGM Results — Apr 12, 2024 Risk: medium
  On April 9, 2024, uniQure N.V. announced changes to its executive team, including the appointment of Dr. Olav Hellebostad as Chief Medical Officer and the depar
• uniQure N.V. Files 8-K on Financial Condition — Feb 28, 2024 Risk: medium
  uniQure N.V. filed an 8-K on February 28, 2024, regarding its results of operations and financial condition. The filing, under SEC File Number 001-36294, indica

Popular Companies

AAPL · TSLA · MSFT · AMZN · GOOGL · META · NVDA · JPM · BRK-B · V · JNJ · UNH · XOM · WMT · MA · PG · HD · DIS · BAC · NFLX